APO Research
Talk to an analyst

APO RESEARCH · REPORT

IBS-C Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global IBS-C Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025193 pages

Choose your research edition.

Industry ResearchIBS-C Drugs Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal IBS-C Drugs Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal IBS-C Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IBS-C Drugs Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal IBS-C Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global IBS-C Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for IBS-C Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IBS-C Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IBS-C Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for IBS-C Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of IBS-C Drugs include Abbott Laboratories, Actavis Nordic A/S, Albireo Pharma Inc, Ardelyx, Inc, Astellas Pharmaceuticals, Bama-Geve, SLU, Catalent Pharmaceuticals Solutions, Ferring BV and Ironwood Pharmaceuticals, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global IBS-C Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IBS-C Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IBS-C Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the IBS-C Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

IBS-C Drugs Segment by Company

Abbott Laboratories

Actavis Nordic A/S

Albireo Pharma Inc

Ardelyx, Inc

Astellas Pharmaceuticals

Bama-Geve, SLU

Catalent Pharmaceuticals Solutions

Ferring BV

Ironwood Pharmaceuticals, Inc

Norgine B.V

Novartis Pharma Ag

Ono Pharmaceutical Co., Ltd

Prometheus Laboratories Inc

Salix Pharmaceuticals Ltd

Sucampo Pharmaceuticals

Synergy Pharmaceuticals

Synthetic Biologics, Inc

Teva Pharmaceutical Industries

The Menarini Group

Yuhan Corp

Astrazeneca Plc

Nestle

IBS-C Drugs Segment by Type

Stimulant Laxatives

Linaclotide

Lubiprostone

Osmotic Laxatives

Others

IBS-C Drugs Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

IBS-C Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IBS-C Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IBS-C Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IBS-C Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the IBS-C Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of IBS-C Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of IBS-C Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of IBS-C Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. IBS-C Drugs Industry Trends Table 2. IBS-C Drugs Industry Drivers Table 3. IBS-C Drugs Industry Opportunities and Challenges Table 4. IBS-C Drugs Industry Restraints Table 5. Global IBS-C Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global IBS-C Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global IBS-C Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global IBS-C Drugs Sales Market Share by Manufacturers Table 9. Global IBS-C Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global IBS-C Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global IBS-C Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global IBS-C Drugs Manufacturers, Product Type & Application Table 13. Global IBS-C Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global IBS-C Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Stimulant Laxatives Table 17. Major Manufacturers of Linaclotide Table 18. Major Manufacturers of Lubiprostone Table 19. Major Manufacturers of Osmotic Laxatives Table 20. Major Manufacturers of Others Table 21. Global IBS-C Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 23. Global IBS-C Drugs Sales by Type (2027-2032) & (K Units) Table 24. Global IBS-C Drugs Sales Market Share by Type (2021-2026) Table 25. Global IBS-C Drugs Sales Market Share by Type (2027-2032) Table 26. Global IBS-C Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global IBS-C Drugs Revenue by Type (2021-2026) & (K Units) Table 28. Global IBS-C Drugs Revenue by Type (2027-2032) & (K Units) Table 29. Global IBS-C Drugs Revenue Market Share by Type (2021-2026) Table 30. Global IBS-C Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Pharmacies Table 32. Major Manufacturers of Online Pharmacies Table 33. Major Manufacturers of Retail Pharmacies Table 34. Global IBS-C Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 36. Global IBS-C Drugs Sales by Application (2027-2032) & (K Units) Table 37. Global IBS-C Drugs Sales Market Share by Application (2021-2026) Table 38. Global IBS-C Drugs Sales Market Share by Application (2027-2032) Table 39. Global IBS-C Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global IBS-C Drugs Revenue by Application (2021-2026) & (K Units) Table 41. Global IBS-C Drugs Revenue by Application (2027-2032) & (K Units) Table 42. Global IBS-C Drugs Revenue Market Share by Application (2021-2026) Table 43. Global IBS-C Drugs Revenue Market Share by Application (2027-2032) Table 44. Global IBS-C Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global IBS-C Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global IBS-C Drugs Sales Market Share by Region (2021-2026) Table 47. Global IBS-C Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global IBS-C Drugs Sales Forecasted Market Share by Region (2027-2032) Table 49. North America IBS-C Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 51. North America IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 52. Europe IBS-C Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 54. Europe IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific IBS-C Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa IBS-C Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa IBS-C Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global IBS-C Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global IBS-C Drugs Revenue by Region (2021-2026) & (US$ Million) Table 63. Global IBS-C Drugs Revenue by Region (2027-2032) & (US$ Million) Table 64. Global IBS-C Drugs Revenue Market Share by Region (2021-2026) Table 65. Global IBS-C Drugs Revenue Market Share by Region (2027-2032) Table 66. Abbott Laboratories Company Information Table 67. Abbott Laboratories Business Overview Table 68. Abbott Laboratories IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Abbott Laboratories IBS-C Drugs Product Portfolio Table 70. Abbott Laboratories Recent Development Table 71. Actavis Nordic A/S Company Information Table 72. Actavis Nordic A/S Business Overview Table 73. Actavis Nordic A/S IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Actavis Nordic A/S IBS-C Drugs Product Portfolio Table 75. Actavis Nordic A/S Recent Development Table 76. Albireo Pharma Inc Company Information Table 77. Albireo Pharma Inc Business Overview Table 78. Albireo Pharma Inc IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Albireo Pharma Inc IBS-C Drugs Product Portfolio Table 80. Albireo Pharma Inc Recent Development Table 81. Ardelyx, Inc Company Information Table 82. Ardelyx, Inc Business Overview Table 83. Ardelyx, Inc IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Ardelyx, Inc IBS-C Drugs Product Portfolio Table 85. Ardelyx, Inc Recent Development Table 86. Astellas Pharmaceuticals Company Information Table 87. Astellas Pharmaceuticals Business Overview Table 88. Astellas Pharmaceuticals IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Astellas Pharmaceuticals IBS-C Drugs Product Portfolio Table 90. Astellas Pharmaceuticals Recent Development Table 91. Bama-Geve, SLU Company Information Table 92. Bama-Geve, SLU Business Overview Table 93. Bama-Geve, SLU IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Bama-Geve, SLU IBS-C Drugs Product Portfolio Table 95. Bama-Geve, SLU Recent Development Table 96. Catalent Pharmaceuticals Solutions Company Information Table 97. Catalent Pharmaceuticals Solutions Business Overview Table 98. Catalent Pharmaceuticals Solutions IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Catalent Pharmaceuticals Solutions IBS-C Drugs Product Portfolio Table 100. Catalent Pharmaceuticals Solutions Recent Development Table 101. Ferring BV Company Information Table 102. Ferring BV Business Overview Table 103. Ferring BV IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Ferring BV IBS-C Drugs Product Portfolio Table 105. Ferring BV Recent Development Table 106. Ironwood Pharmaceuticals, Inc Company Information Table 107. Ironwood Pharmaceuticals, Inc Business Overview Table 108. Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Ironwood Pharmaceuticals, Inc IBS-C Drugs Product Portfolio Table 110. Ironwood Pharmaceuticals, Inc Recent Development Table 111. Norgine B.V Company Information Table 112. Norgine B.V Business Overview Table 113. Norgine B.V IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Norgine B.V IBS-C Drugs Product Portfolio Table 115. Norgine B.V Recent Development Table 116. Novartis Pharma Ag Company Information Table 117. Novartis Pharma Ag Business Overview Table 118. Novartis Pharma Ag IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Novartis Pharma Ag IBS-C Drugs Product Portfolio Table 120. Novartis Pharma Ag Recent Development Table 121. Ono Pharmaceutical Co., Ltd Company Information Table 122. Ono Pharmaceutical Co., Ltd Business Overview Table 123. Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Ono Pharmaceutical Co., Ltd IBS-C Drugs Product Portfolio Table 125. Ono Pharmaceutical Co., Ltd Recent Development Table 126. Prometheus Laboratories Inc Company Information Table 127. Prometheus Laboratories Inc Business Overview Table 128. Prometheus Laboratories Inc IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Prometheus Laboratories Inc IBS-C Drugs Product Portfolio Table 130. Prometheus Laboratories Inc Recent Development Table 131. Salix Pharmaceuticals Ltd Company Information Table 132. Salix Pharmaceuticals Ltd Business Overview Table 133. Salix Pharmaceuticals Ltd IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Salix Pharmaceuticals Ltd IBS-C Drugs Product Portfolio Table 135. Salix Pharmaceuticals Ltd Recent Development Table 136. Sucampo Pharmaceuticals Company Information Table 137. Sucampo Pharmaceuticals Business Overview Table 138. Sucampo Pharmaceuticals IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Sucampo Pharmaceuticals IBS-C Drugs Product Portfolio Table 140. Sucampo Pharmaceuticals Recent Development Table 141. Synergy Pharmaceuticals Company Information Table 142. Synergy Pharmaceuticals Business Overview Table 143. Synergy Pharmaceuticals IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Synergy Pharmaceuticals IBS-C Drugs Product Portfolio Table 145. Synergy Pharmaceuticals Recent Development Table 146. Synthetic Biologics, Inc Company Information Table 147. Synthetic Biologics, Inc Business Overview Table 148. Synthetic Biologics, Inc IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Synthetic Biologics, Inc IBS-C Drugs Product Portfolio Table 150. Synthetic Biologics, Inc Recent Development Table 151. Teva Pharmaceutical Industries Company Information Table 152. Teva Pharmaceutical Industries Business Overview Table 153. Teva Pharmaceutical Industries IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Teva Pharmaceutical Industries IBS-C Drugs Product Portfolio Table 155. Teva Pharmaceutical Industries Recent Development Table 156. The Menarini Group Company Information Table 157. The Menarini Group Business Overview Table 158. The Menarini Group IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. The Menarini Group IBS-C Drugs Product Portfolio Table 160. The Menarini Group Recent Development Table 161. Yuhan Corp Company Information Table 162. Yuhan Corp Business Overview Table 163. Yuhan Corp IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. Yuhan Corp IBS-C Drugs Product Portfolio Table 165. Yuhan Corp Recent Development Table 166. Astrazeneca Plc Company Information Table 167. Astrazeneca Plc Business Overview Table 168. Astrazeneca Plc IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 169. Astrazeneca Plc IBS-C Drugs Product Portfolio Table 170. Astrazeneca Plc Recent Development Table 171. Nestle Company Information Table 172. Nestle Business Overview Table 173. Nestle IBS-C Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 174. Nestle IBS-C Drugs Product Portfolio Table 175. Nestle Recent Development Table 176. Key Raw Materials Table 177. Raw Materials Key Suppliers Table 178. IBS-C Drugs Distributors List Table 179. IBS-C Drugs Customers List Table 180. Research Programs/Design for This Report Table 181. Authors List of This Report Table 182. Secondary Sources Table 183. Primary Sources List of Figures Figure 1. IBS-C Drugs Product Image Figure 2. Global IBS-C Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IBS-C Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global IBS-C Drugs Sales (2021-2032) & (K Units) Figure 5. Global IBS-C Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 IBS-C Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Stimulant Laxatives Image Figure 9. Linaclotide Image Figure 10. Lubiprostone Image Figure 11. Osmotic Laxatives Image Figure 12. Others Image Figure 13. Global IBS-C Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global IBS-C Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global IBS-C Drugs Sales Market Share by Type (2021-2032) Figure 16. Global IBS-C Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global IBS-C Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global IBS-C Drugs Revenue Market Share by Type (2021-2032) Figure 19. Hospital Pharmacies Image Figure 20. Online Pharmacies Image Figure 21. Retail Pharmacies Image Figure 22. Global IBS-C Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global IBS-C Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global IBS-C Drugs Sales Market Share by Application (2021-2032) Figure 25. Global IBS-C Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global IBS-C Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global IBS-C Drugs Revenue Market Share by Application (2021-2032) Figure 28. North America IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America IBS-C Drugs Sales Market Share by Country (2021-2032) Figure 30. U.S. IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe IBS-C Drugs Sales Market Share by Country (2021-2032) Figure 35. Germany IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific IBS-C Drugs Sales Market Share by Country (2021-2032) Figure 42. China IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa IBS-C Drugs Sales Market Share by Country (2021-2032) Figure 50. Brazil IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile IBS-C Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global IBS-C Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global IBS-C Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America IBS-C Drugs Revenue (2021-2032) & (US$ Million) Figure 61. North America IBS-C Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe IBS-C Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Europe IBS-C Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific IBS-C Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific IBS-C Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa IBS-C Drugs Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa IBS-C Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. IBS-C Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. IBS-C Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Stimulant Laxatives
  • Linaclotide
  • Lubiprostone
  • Osmotic Laxatives
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Abbott Laboratories
  • Actavis Nordic A/S
  • Albireo Pharma Inc
  • Ardelyx, Inc
  • Astellas Pharmaceuticals
  • Bama-Geve, SLU
  • Catalent Pharmaceuticals Solutions
  • Ferring BV
  • Ironwood Pharmaceuticals, Inc
  • Norgine B.V
  • Novartis Pharma Ag
  • Ono Pharmaceutical Co., Ltd
  • Prometheus Laboratories Inc
  • Salix Pharmaceuticals Ltd
  • Sucampo Pharmaceuticals
  • Synergy Pharmaceuticals
  • Synthetic Biologics, Inc
  • Teva Pharmaceutical Industries
  • The Menarini Group
  • Yuhan Corp
  • Astrazeneca Plc
  • Nestle

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global IBS-C Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global IBS-C Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global IBS-C Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global IBS-C Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global IBS-C Drugs Market Dynamics
  1. 2.1 IBS-C Drugs Industry Trends
  2. 2.2 IBS-C Drugs Industry Drivers
  3. 2.3 IBS-C Drugs Industry Opportunities and Challenges
  4. 2.4 IBS-C Drugs Industry Restraints
3 IBS-C Drugs Market by Manufacturers
  1. 3.1 Global IBS-C Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global IBS-C Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global IBS-C Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global IBS-C Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global IBS-C Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global IBS-C Drugs Manufacturers, Product Type & Application
  7. 3.7 Global IBS-C Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global IBS-C Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 IBS-C Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 IBS-C Drugs Tier 1, Tier 2, and Tier 3
4 IBS-C Drugs Market by Type
  1. 4.1 IBS-C Drugs Type Introduction
  2. 4.1.1 Stimulant Laxatives
  3. 4.1.2 Linaclotide
  4. 4.1.3 Lubiprostone
  5. 4.1.4 Osmotic Laxatives
  6. 4.1.5 Others
  7. 4.2 Global IBS-C Drugs Sales by Type
  8. 4.2.1 Global IBS-C Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global IBS-C Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global IBS-C Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global IBS-C Drugs Revenue by Type
  12. 4.3.1 Global IBS-C Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global IBS-C Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global IBS-C Drugs Revenue Market Share by Type (2021-2032)
5 IBS-C Drugs Market by Application
  1. 5.1 IBS-C Drugs Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global IBS-C Drugs Sales by Application
  6. 5.2.1 Global IBS-C Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global IBS-C Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global IBS-C Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global IBS-C Drugs Revenue by Application
  10. 5.3.1 Global IBS-C Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global IBS-C Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global IBS-C Drugs Revenue Market Share by Application (2021-2032)
6 Global IBS-C Drugs Sales by Region
  1. 6.1 Global IBS-C Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global IBS-C Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global IBS-C Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global IBS-C Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America IBS-C Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America IBS-C Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe IBS-C Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe IBS-C Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific IBS-C Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific IBS-C Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa IBS-C Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa IBS-C Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global IBS-C Drugs Revenue by Region
  1. 7.1 Global IBS-C Drugs Revenue by Region
  2. 7.1.1 Global IBS-C Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global IBS-C Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global IBS-C Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global IBS-C Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America IBS-C Drugs Revenue (2021-2032)
  8. 7.2.2 North America IBS-C Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe IBS-C Drugs Revenue (2021-2032)
  11. 7.3.2 Europe IBS-C Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific IBS-C Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific IBS-C Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa IBS-C Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa IBS-C Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott Laboratories
  2. 8.1.1 Abbott Laboratories Company Information
  3. 8.1.2 Abbott Laboratories Business Overview
  4. 8.1.3 Abbott Laboratories IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Laboratories IBS-C Drugs Product Portfolio
  6. 8.1.5 Abbott Laboratories Recent Developments
  7. 8.2 Actavis Nordic A/S
  8. 8.2.1 Actavis Nordic A/S Company Information
  9. 8.2.2 Actavis Nordic A/S Business Overview
  10. 8.2.3 Actavis Nordic A/S IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Actavis Nordic A/S IBS-C Drugs Product Portfolio
  12. 8.2.5 Actavis Nordic A/S Recent Developments
  13. 8.3 Albireo Pharma Inc
  14. 8.3.1 Albireo Pharma Inc Company Information
  15. 8.3.2 Albireo Pharma Inc Business Overview
  16. 8.3.3 Albireo Pharma Inc IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Albireo Pharma Inc IBS-C Drugs Product Portfolio
  18. 8.3.5 Albireo Pharma Inc Recent Developments
  19. 8.4 Ardelyx, Inc
  20. 8.4.1 Ardelyx, Inc Company Information
  21. 8.4.2 Ardelyx, Inc Business Overview
  22. 8.4.3 Ardelyx, Inc IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Ardelyx, Inc IBS-C Drugs Product Portfolio
  24. 8.4.5 Ardelyx, Inc Recent Developments
  25. 8.5 Astellas Pharmaceuticals
  26. 8.5.1 Astellas Pharmaceuticals Company Information
  27. 8.5.2 Astellas Pharmaceuticals Business Overview
  28. 8.5.3 Astellas Pharmaceuticals IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Astellas Pharmaceuticals IBS-C Drugs Product Portfolio
  30. 8.5.5 Astellas Pharmaceuticals Recent Developments
  31. 8.6 Bama-Geve, SLU
  32. 8.6.1 Bama-Geve, SLU Company Information
  33. 8.6.2 Bama-Geve, SLU Business Overview
  34. 8.6.3 Bama-Geve, SLU IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bama-Geve, SLU IBS-C Drugs Product Portfolio
  36. 8.6.5 Bama-Geve, SLU Recent Developments
  37. 8.7 Catalent Pharmaceuticals Solutions
  38. 8.7.1 Catalent Pharmaceuticals Solutions Company Information
  39. 8.7.2 Catalent Pharmaceuticals Solutions Business Overview
  40. 8.7.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Catalent Pharmaceuticals Solutions IBS-C Drugs Product Portfolio
  42. 8.7.5 Catalent Pharmaceuticals Solutions Recent Developments
  43. 8.8 Ferring BV
  44. 8.8.1 Ferring BV Company Information
  45. 8.8.2 Ferring BV Business Overview
  46. 8.8.3 Ferring BV IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ferring BV IBS-C Drugs Product Portfolio
  48. 8.8.5 Ferring BV Recent Developments
  49. 8.9 Ironwood Pharmaceuticals, Inc
  50. 8.9.1 Ironwood Pharmaceuticals, Inc Company Information
  51. 8.9.2 Ironwood Pharmaceuticals, Inc Business Overview
  52. 8.9.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ironwood Pharmaceuticals, Inc IBS-C Drugs Product Portfolio
  54. 8.9.5 Ironwood Pharmaceuticals, Inc Recent Developments
  55. 8.10 Norgine B.V
  56. 8.10.1 Norgine B.V Company Information
  57. 8.10.2 Norgine B.V Business Overview
  58. 8.10.3 Norgine B.V IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Norgine B.V IBS-C Drugs Product Portfolio
  60. 8.10.5 Norgine B.V Recent Developments
  61. 8.11 Novartis Pharma Ag
  62. 8.11.1 Novartis Pharma Ag Company Information
  63. 8.11.2 Novartis Pharma Ag Business Overview
  64. 8.11.3 Novartis Pharma Ag IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novartis Pharma Ag IBS-C Drugs Product Portfolio
  66. 8.11.5 Novartis Pharma Ag Recent Developments
  67. 8.12 Ono Pharmaceutical Co., Ltd
  68. 8.12.1 Ono Pharmaceutical Co., Ltd Company Information
  69. 8.12.2 Ono Pharmaceutical Co., Ltd Business Overview
  70. 8.12.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Ono Pharmaceutical Co., Ltd IBS-C Drugs Product Portfolio
  72. 8.12.5 Ono Pharmaceutical Co., Ltd Recent Developments
  73. 8.13 Prometheus Laboratories Inc
  74. 8.13.1 Prometheus Laboratories Inc Company Information
  75. 8.13.2 Prometheus Laboratories Inc Business Overview
  76. 8.13.3 Prometheus Laboratories Inc IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Prometheus Laboratories Inc IBS-C Drugs Product Portfolio
  78. 8.13.5 Prometheus Laboratories Inc Recent Developments
  79. 8.14 Salix Pharmaceuticals Ltd
  80. 8.14.1 Salix Pharmaceuticals Ltd Company Information
  81. 8.14.2 Salix Pharmaceuticals Ltd Business Overview
  82. 8.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Salix Pharmaceuticals Ltd IBS-C Drugs Product Portfolio
  84. 8.14.5 Salix Pharmaceuticals Ltd Recent Developments
  85. 8.15 Sucampo Pharmaceuticals
  86. 8.15.1 Sucampo Pharmaceuticals Company Information
  87. 8.15.2 Sucampo Pharmaceuticals Business Overview
  88. 8.15.3 Sucampo Pharmaceuticals IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Sucampo Pharmaceuticals IBS-C Drugs Product Portfolio
  90. 8.15.5 Sucampo Pharmaceuticals Recent Developments
  91. 8.16 Synergy Pharmaceuticals
  92. 8.16.1 Synergy Pharmaceuticals Company Information
  93. 8.16.2 Synergy Pharmaceuticals Business Overview
  94. 8.16.3 Synergy Pharmaceuticals IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Synergy Pharmaceuticals IBS-C Drugs Product Portfolio
  96. 8.16.5 Synergy Pharmaceuticals Recent Developments
  97. 8.17 Synthetic Biologics, Inc
  98. 8.17.1 Synthetic Biologics, Inc Company Information
  99. 8.17.2 Synthetic Biologics, Inc Business Overview
  100. 8.17.3 Synthetic Biologics, Inc IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Synthetic Biologics, Inc IBS-C Drugs Product Portfolio
  102. 8.17.5 Synthetic Biologics, Inc Recent Developments
  103. 8.18 Teva Pharmaceutical Industries
  104. 8.18.1 Teva Pharmaceutical Industries Company Information
  105. 8.18.2 Teva Pharmaceutical Industries Business Overview
  106. 8.18.3 Teva Pharmaceutical Industries IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Teva Pharmaceutical Industries IBS-C Drugs Product Portfolio
  108. 8.18.5 Teva Pharmaceutical Industries Recent Developments
  109. 8.19 The Menarini Group
  110. 8.19.1 The Menarini Group Company Information
  111. 8.19.2 The Menarini Group Business Overview
  112. 8.19.3 The Menarini Group IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 The Menarini Group IBS-C Drugs Product Portfolio
  114. 8.19.5 The Menarini Group Recent Developments
  115. 8.20 Yuhan Corp
  116. 8.20.1 Yuhan Corp Company Information
  117. 8.20.2 Yuhan Corp Business Overview
  118. 8.20.3 Yuhan Corp IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Yuhan Corp IBS-C Drugs Product Portfolio
  120. 8.20.5 Yuhan Corp Recent Developments
  121. 8.21 Astrazeneca Plc
  122. 8.21.1 Astrazeneca Plc Company Information
  123. 8.21.2 Astrazeneca Plc Business Overview
  124. 8.21.3 Astrazeneca Plc IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Astrazeneca Plc IBS-C Drugs Product Portfolio
  126. 8.21.5 Astrazeneca Plc Recent Developments
  127. 8.22 Nestle
  128. 8.22.1 Nestle Company Information
  129. 8.22.2 Nestle Business Overview
  130. 8.22.3 Nestle IBS-C Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Nestle IBS-C Drugs Product Portfolio
  132. 8.22.5 Nestle Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 IBS-C Drugs Value Chain Analysis
  2. 9.1.1 IBS-C Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 IBS-C Drugs Production Mode & Process
  6. 9.2 IBS-C Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 IBS-C Drugs Distributors
  9. 9.2.3 IBS-C Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst